Dublin, Dec. 27, 2024 (GLOBE NEWSWIRE) -- The "Schizophrenia: Seven-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering.
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the schizophrenia market through 2031.
The global schizophrenia marketplace is forecast to experience steady growth during the forecast period. This growth will be driven primarily by the launch of five adjunctive therapies that are designed to be used in combination with the other marketed antipsychotics. These include Neurocrine Biosciences' Ingrezza (valbenazine) and NBI-1117568, Bristol Myers Squibb's Cobenfy (trospium chloride + xanomeline), and Boehringer Ingelheim's Iclepertin/BI-425809. Although the majority of the therapies that are already in the market are genericized, patent expiries of long-acting injectable (LAI) atypical antipsychotics such as Abilify Maintena and Aristada are expected to curtail market growth.
This model covers the market forecast for schizophrenia marketed therapies and late-stage pipeline candidates.
Report Scope
- Overview of Schizophrenia, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized schizophrenia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the schizophrenia therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for schizophrenia treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global schizophrenia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM schizophrenia therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM schizophrenia therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Key Topics Covered:
1 Schizophrenia: Executive Summary
1.1 The schizophrenia market will grow to $17 billion.
1.2 Key players will struggle to maintain their competitive position.
1.3 While outlook for schizophrenia management made headway, opportunities remain to improve patient outcomes.
1.4 The entry of adjunctive therapies will shape the schizophrenia market.
1.5 What do physicians think?
2 Introduction
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities.
4.3 Global and historical trends
4.4 7MM forecast methodology.
4.4.1 Sources used.
4.4.2 Forecast assumptions and methods.
4.4.3 Forecast assumptions and methods: 12-month total prevalent cases of schizophrenia.
4.5 Epidemiological Forecast for Schizophrenia (2021-31)
4.5.1 12-Month total prevalent cases of schizophrenia
4.5.2 12-Month diagnosed prevalent cases of schizophrenia
4.5.3 Age-specific 12-month diagnosed prevalent cases of schizophrenia.
4.5.4 Sex-specific 12-month diagnosed prevalent cases of schizophrenia.
4.6 Discussion
5 Disease Management
5.1 Diagnosis overview
5.2 Treatment overview
5.3 Non-pharmacological management of schizophrenia
6 Competitive Assessment
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Development of therapies to target cognitive impairment associated with schizophrenia
7.3 Development of therapies to target negative symptoms.
7.4 Development of therapies for treatment-resistant patients
7.5 Improved patient insight and adherence to treatment
8 R&D Strategies
8.1 Overview
8.1.1 Reformulations and innovative drug delivery systems
8.1.2 Novel MOAs
8.1.3 Development of adjunctive therapies
8.1.4 Digital therapeutics
8.2 Clinical trial design
8.2.1 Clinical endpoints
8.2.2 Patient Recruitment
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-making trends
12 Market Outlook
12.1 Global Markets
12.2 US
12.3 5EU
12.4 Japan
Company Coverage:
- Alexza Pharmaceuticals
- Alkermes
- Astellas
- AstraZeneca
- Biogen Inc
- BioXcel Therapeutics Inc
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb
- Eli Lilly
- Gedeon Richter
- Hisamitsu Pharmaceuticals
- Indivior
- Intra-Cellular Therapies Inc
- Johnson & Johnson
- Laboratorios Farmaceuticos Rovi
- Lundbeck
- Luye Pharma Group
- Lyndra Therapeutics Inc.
- MedinCell
- Merck & Co
- Neurocrine Biosciences Inc
- Newron Pharmaceuticals SpA
- Otsuka Pharmaceutical Co Ltd
- Reviva Pharmaceuticals Inc
- Sumitomo Dainippon
- Sumitomo Pharma Co Ltd
- Teva Pharmaceutical Industries Ltd
- Vanda Pharmaceuticals Inc
For more information about this report visit https://www.researchandmarkets.com/r/u7jq1n
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
